Cancer immunotherapy for dogs: two US developments combined into one drug — what's known, how far along it is and what it means for owners

What was announced in Boston

On 26 October 2026, at the Animal Health, Nutrition and Technology Innovation (AHNTI) conference in Boston, the US company VETARYS announced a scientific collaboration with Antigenesis Biologics. VETARYS also obtained an option on an exclusive licence to Antigenesis's candidate — a combination immunotherapy for treating solid tumours in dogs. Solid tumours are those that form a firm mass, as opposed to blood cancers.

Who these companies are

VETARYS, formerly known as VetrixBio, is a Massachusetts biotech company developing biological medicines for pets; its pipeline includes treatments for osteoarthritis and cancer. Antigenesis Biologics works on veterinary medicines for oncology and endocrinology, and its main focus at present is cancer in dogs. The company describes its candidates as first-in-class antibody drugs built on advances in human cancer immunotherapy.

What the drug is

The Antigenesis candidate is a fusion protein that combines two immunotherapies. The idea of immunotherapy is not to destroy a tumour directly with toxic drugs or radiation, but to help the animal's own immune system recognise and attack cancer cells. Tumours are able to "hide" from the immune system and suppress it; immunotherapy removes that protection or boosts the immune response.

In people, this approach has transformed the treatment of several cancers over the past fifteen years. Drugs that release the "brakes" on immune cells have allowed many patients with melanoma and lung cancer to live for years, where the prognosis used to be measured in months. Veterinary companies are trying to bring these ideas to dogs — but dogs need their own "caninised" versions of antibodies, otherwise the animal's body treats the human protein as foreign.

The drug combines two immunotherapies that together have shown a compelling improvement in survival.

Peter Hanson, chief scientific officer of VETARYS

The companies have not yet disclosed exactly which immunotherapies the drug contains or which molecules they target. Nor have specific tumour types been named, beyond the fact that it is aimed at solid tumours.

What is known about the results

So far the companies have cited only results in mice — in a model of severe melanoma. According to them, the drug improved survival and shrank tumours. The announcement contains no data from trials in dogs, no clinical trial phase and no timeline for reaching the market. The financial terms of the agreement have not been disclosed either. The mouse melanoma model is a laboratory system in which an aggressive tumour is deliberately induced in animals to check quickly whether a drug has any effect at all. It is useful for selecting promising molecules but says little about how a drug will behave in a dog with a naturally occurring tumour.

It is important to see this in the right light: success in mice is only the first step. Many drugs that worked well in laboratory models later failed to show effectiveness in sick animals or turned out to be too toxic.

Why the companies are betting on an injection under the skin

According to Hanson, standard cancer treatment for dogs is still largely limited to radiotherapy and chemotherapy. The aim of the new development is a drug that is injected under the skin and can be used by first-opinion vets, complementing the work of veterinary oncologists.

That is a genuinely important goal. Animal cancer centres are far from available in every town, few clinics offer radiotherapy, and travelling for treatment is a big ordeal for an elderly, sick dog and its owners. If effective treatment could be given by your own vet, it would be open to many more dogs. An injection under the skin is also simpler and less stressful for a dog than a drip or daily radiotherapy under anaesthetic.

How cancer in dogs is treated today

Cancer is one of the main causes of death in older dogs. The most common cancers in dogs are skin tumours, including mast cell tumours, as well as lymphoma, mammary tumours, bone and blood vessel tumours, and oral melanoma. The main treatments are:

• surgery — removing the tumour, sometimes with surrounding tissue and lymph nodes;
• chemotherapy — in dogs it is usually given at gentler doses, and most animals tolerate it better than people do: severe nausea and hair loss are rare;
• radiotherapy — at specialist centres;
• immunotherapy and targeted drugs — still few in number, but growing.

The aim of treatment in animals is not only to prolong life but also to preserve its quality. Many owners hesitate to treat for fear that their dog will suffer. Veterinary oncologists usually tailor treatment to keep side effects to a minimum, and change or stop it if the dog's wellbeing deteriorates.

The long road from mouse to clinic

Before a new drug reaches vets, it has to pass through several stages: safety testing, dose-finding, clinical trials in dogs with tumours treated with their owners' consent and, finally, approval by regulators. This usually takes years. The announced collaboration is at the very start of that road. In the US, veterinary drugs are approved by the FDA, while many biological products, including vaccines and some antibodies, are licensed by the Department of Agriculture. For drugs against serious diseases with no existing treatment, conditional approval is sometimes possible, but even that requires evidence of safety and reasonable data on effectiveness.

Dogs help people too

In dogs, cancer arises spontaneously, as it does in people — they live in the same environment and have immune systems and tumours similar to ours. That is why treating cancer in dogs is part of what is called comparative oncology: research that helps animals often provides valuable data for human medicine too. It is no coincidence that many veterinary immunotherapies, like the Antigenesis drug, are based on developments for people. A classic example is osteosarcoma, a bone cancer: it is far more common in large-breed dogs than in people and closely resembles osteosarcoma in children and teenagers. Research into treating dogs with this tumour also helps paediatric oncology.

What this means for the UK and Europe

For owners in the UK and Europe, this is news about the future for now: the drug has not been tested in dogs and is not authorised in any country. If it reaches approval in the US, it would need separate authorisation to be sold elsewhere. In the EU, biotech veterinary medicines, including antibodies, are authorised centrally through the European Medicines Agency (EMA); in the UK, veterinary medicines are authorised by the Veterinary Medicines Directorate.

The technology itself is no longer exotic for dogs here: antibody medicines for dogs are already authorised — for example, for allergic itch and for osteoarthritis pain. This shows that antibody treatment works in dogs and is used safely in ordinary practices. In oncology, such drugs are only just starting to appear. Some veterinary schools and referral hospitals run clinical trials of new cancer treatments for dogs, and owners can ask their vet or a veterinary oncologist about them.

How to spot a tumour in your dog earlier

The earlier cancer is found, the more treatment options there are. Vets advise:

• once a month, feel your dog all over — skin, belly, the lymph nodes under the jaw and behind the knees, and the mammary glands in bitches;
• show your vet any lump that is larger than a pea or hasn't gone after a month;
• don't "wait and see" — ask for a fine-needle sample: it's a quick, almost painless procedure that often shows straight away what the lump is;
• watch for unexplained weight loss, sores that don't heal, bleeding, lameness, breathing difficulties, bad breath and loss of appetite.

Be especially vigilant with dogs over 8–10 years old and with breeds that are more prone to certain cancers — it's best to ask your vet or breed club about this.

If your dog has been diagnosed with cancer

Don't make decisions in a hurry. Ask your vet to explain what type of tumour it is, how aggressive it is and what the options are — from surgery and chemotherapy to palliative care that helps your dog live without pain. If possible, get a referral to a veterinary oncologist. Ask about clinical trials too: taking part can sometimes give access to new treatments. And don't be shy about asking what treatment will cost: a good vet will discuss several options and help you choose one that suits both your dog and your family.

What happens next

VETARYS and Antigenesis will study the drug together, and if the results are confirmed, VETARYS may take an exclusive licence. Dog trials, timelines and treatment costs have not yet been announced. Cancer immunotherapy for dogs is one of the most exciting areas of veterinary medicine, but it will be some time before such drugs become routine in clinics. Until then, the most important thing owners can do is get any suspicious changes checked by a vet in good time.